BamSEC and AlphaSense Join Forces
Learn More

Allogene Therapeutics Inc.

NASDAQ: ALLO    
Share price (12/20/24): $1.87    
Market cap (12/20/24): $392 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.7
from 10-Q 2 pages Amendment 1 to Strategic Collaboration Agreement
12/34/56
EX-10.6
from 10-Q 3 pages Agreement
12/34/56
EX-10.4
from 10-Q 23 pages Amendment and Settlement Agreement
12/34/56
EX-10.3
from 10-Q 9 pages First Amendment to Exclusive License Agreement
12/34/56
EX-10.2
from 10-Q 37 pages Amended and Restated Shareholders’ Agreement
12/34/56
EX-10.1
from 10-Q 43 pages Share Exchange Agreement
12/34/56
EX-10.1
from 8-K 13 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Allogene Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: September 26, 2018 Amended: April 16, 2019 Amended: September 17, 2019 Amended: September 13, 2023 Amended: March 28, 2024
12/34/56
EX-10.30
from 10-K 38 pages Strategic Collaboration Agreement Between Foresight Diagnostics, Inc. and Allogene Therapeutics, Inc. Dated as of January 3, 2024 Strategic Collaboration Agreement
12/34/56
EX-10.18
from 10-K 46 pages Amended and Restated Collaboration and License Agreement
12/34/56
EX-10.10
from 10-K 1 page First Amendment to Consulting Agreement
12/34/56
EX-10.7
from 10-K 3 pages Allogene Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: September 26, 2018 Amended: April 16, 2019 Amended: September 17, 2019 Amended: September 13, 2023
12/34/56
EX-10.4
from 10-Q 6 pages Allogene Therapeutics, Inc. Shares of Common Stock ($0.001 Par Value) Amendment No. 2 to the Sales Agreement
12/34/56
EX-10.3
from 10-Q 88 pages Asset Contribution Agreement by and Between Pfizer Inc. and Allogene Therapeutics, Inc. Dated as of April 2, 2018
12/34/56
EX-10.2
from 10-Q 19 pages October 12, 2023 Geoffrey Parker Re: Employment Letter of Agreement
12/34/56
EX-10.1
from 10-Q 21 pages August 11, 2023 Earl Douglas Re: Employment Letter of Agreement (“Agreement”) 1. Title; Reporting; Duties. (A)when You Commence Employment With Allogene, You Shall Be Employed in the Position of Svp, General Counsel, Shall Report Directly to David Chang, Chief Executive Officer and Shall Perform the Duties and Responsibilities That the Company Assigns to You
12/34/56
EX-10.3
from 10-Q 21 pages April 18, 2023 Timothy Moore Re: Employment Letter of Agreement (“Agreement”) 1. Title; Reporting; Duties. 2. Compensation
12/34/56
EX-10.2
from 10-Q 8 pages Consulting Agreement
12/34/56
EX-10.1
from 10-Q 9 pages Consulting Agreement
12/34/56
EX-10.13
from 10-K 20 pages December 28, 2022 Zachary Roberts Re: Employment Letter of Agreement (“Agreement”) 1. Title; Reporting; Duties. (A)when You Commence Employment With Allogene, You Shall Be Employed in the Position of Evp, Head of Research & Development, Shall Report Directly to David Chang, Chief Executive Officer and Shall Perform the Duties and Responsibilities That the Company Assigns to You
12/34/56